Market Expert Opinion: Gilead Sciences, NPS Pharma, InterMune, and Halozyme Therapeutics PR Newswire LONDON, December 2, 2013 LONDON, December 2, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Friday, November 29, 2013, the S&P 500 Healthcare sector index ended the day at 638.06, down 0.12%; whereas the S&P 500 Biotechnology industry index posted gains, up 0.22% to 2787.36. The Biotechnology industry shares have gained 5.11% in the last one month and 17.94% in the previous three months, outperforming the S&P 500, which has gained 2.51% and 10.58% during the respective periods.The U.S. equity market finished the dayon a mixed note, the S&P 500 ended the day at1,805.81, down 0.08%; the Dow Jones Industrial Average closed at 16,086.41, down 0.07%; and the NASDAQ Composite finished at4,059.89, up 0.37%.The major movers in the biotechnology industry includedGilead Sciences Inc. (NASDAQ: GILD), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), InterMune Inc. (NASDSAQ: ITMN), and Halozyme Therapeutics Inc. (NYSE: HALO). All these companies are tracked by AAAResearchReports.com. Free technical research on GILD, NPSP, ITMN, and HALO can be downloaded upon signing up at: http://www.aaaresearchreports.com/register/ On Friday, Gilead Sciences Inc.'s stock edged higher to end the day at $74.81, up 0.24% from the previous day's closing price of $74.63. The company's shares vacillated between $74.77 and $75.25 during the trading session. A total of 4.90 million shares were traded, which is below the daily average volume of 8.49 million. The company's shares have gained 5.41% in the last one month and 24.12% in the previous three months, outperforming the S&P 500, which has advanced 2.51% and 10.58% during the respective periods. Moreover, Gilead Sciences Inc.'s stock is trading near its 52-week high of $75.43 and above its 50-day and 200-day moving averages of $67.13 and $56.83, respectively. Sign up and read the complimentary report on GILD at: http://www.AAAResearchReports.com/GILD120213.pdf Shares in NPS Pharmaceuticals Inc. advanced on Friday, even as the broader market ended on a mixed note. The company's shares closed the day 0.42% higher at $26.41, after vacillating between $26.07 and $26.65. A total of 0.70 million shares were traded, which is below the daily average volume of 2.17 million. The company's shares have gained 9.45% in the previous three trading sessions and 5.22% in the last three months, compared to a gain of 0.18% and 10.58% in the S&P 500 during the respective periods. Furthermore, NPS Pharmaceuticals Inc.'s stock is trading above its 200-day moving average of $19.07. The free report on NPSP can be downloaded by signing up now at: http://www.AAAResearchReports.com/NPSP120213.pdf InterMune Inc.'s stock fluctuated between $13.65 and $13.90 before finishing Friday's session 0.14% higher at $13.83. A total of 0.30 million shares were traded, which is below the daily average volume of 1.06 million. The company's shares have gained 7.29% in the previous three trading sessions, outperforming the S&P 500, which has gained 0.18% during the same period. Further, InterMune Inc.'s stock is trading above its 200-day moving average of $11.81. A free report on ITMN can be accessed by registering at: http://www.AAAResearchReports.com/ITMN120213.pdf On Friday, shares in Halozyme Therapeutics Inc. ended the day at $14.76, which is 1.14% lower than the previous day's closing price of $14.93. The company's shares fluctuated between $14.69 and $15.15 during the trading session. A total of 0.61 million shares were traded, which is below the daily average volume of 1.73 million. Despite Friday's losses, the company's shares have surged 27.46% in the last one month and 77.62% in the previous three months, outperforming the S&P 500, which has gained 2.51% and 10.58% during the respective periods. Additionally, Halozyme Therapeutics Inc.'s stock is trading above its 50-day and 200-day moving averages of $11.85 and $8.13, respectively. Register with AAA Research Reports and download research on HALO for free at: http://www.AAAResearchReports.com/HALO120213.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE AAA Research Reports Contact: + 1 (646) 396-9126 : Peter F. Jones: firstname.lastname@example.org
Market Expert Opinion: Gilead Sciences, NPS Pharma, InterMune, and Halozyme Therapeutics
Press spacebar to pause and continue. Press esc to stop.